3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
4
Recruiting
2
Unknown
1
Terminated
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
2
Conditions
Carcinoma, Basal Cell
3
Skin Neoplasms
2
Neoplasms
2
Platinum-Resistant Fallopian Tube Carcinoma
1
Neoplasms, Basal Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Basal Cell Nevus Syndrome
1
Interventions
Blood Specimen Collection
38
pembrolizumab
36
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
18
Exercise
17
Carboplatin
16
Nivolumab
15
atezolizumab
14
Cisplatin
14
Drug Therapy
13
Paclitaxel
12
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
12
Trastuzumab
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Pemetrexed
9
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
HhAntag691
×
Clear all
NCT04341181
2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2
Recruiting
300 enrolled
NCT02925234
2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2
Recruiting
1,550 enrolled